Top

Published in:

Open Access 01-12-2018 | Research

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Authors: Isabel Ortuño-Lizarán, Gema Esquiva, Thomas G. Beach, Geidy E. Serrano, Charles H. Adler, Pedro Lax, Nicolás Cuenca

Published in: Acta Neuropathologica Communications | Issue 1/2018

Abstract

Parkinson’s disease (PD) patients often suffer from non-motor symptoms like sleep dysregulation, mood disturbances or circadian rhythms dysfunction. The melanopsin-containing retinal ganglion cells are involved in the control and regulation of these processes and may be affected in PD, as other retinal and visual implications have been described in the disease. Number and morphology of human melanopsin-containing retinal ganglion cells were evaluated by immunohistochemistry in eyes from donors with PD or control. The Sholl number of intersections, the number of branches, and the number of terminals from the Sholl analysis were significantly reduced in PD melanopsin ganglion cells. Also, the density of these cells significantly decreased in PD compared to controls. Degeneration and impairment of the retinal melanopsin system may affect to sleep and circadian dysfunction reported in PD pathology, and its protection or stimulation may lead to better disease prospect and global quality of life of patients.

Altimus CM, Güler AD, Villa KL, McNeill DS, Legates TA, Hattar S (2008) Rods-cones and melanopsin detect light and dark to modulate sleep independent of image formation. Proc Natl Acad Sci U S A 105:19998–20003. https://doi.org/10.1073/pnas.0808312105 CrossRefPubMedPubMedCentral

Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinsons disease. Brain 132:1128–1145. https://doi.org/10.1093/brain/awp068 CrossRefPubMed

Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2011) Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord 26:2387–2395. https://doi.org/10.1002/mds.23891 CrossRefPubMed

Armstrong RA (2017) Visual dysfunction in Parkinson’s disease. Int Rev Neurobiol 134:921–946. https://doi.org/10.1016/bs.irn.2017.04.007 CrossRefPubMed

Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634. https://doi.org/10.1007/s00401-009-0538-8 CrossRefPubMedPubMedCentral

Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N, Caviness J, Driver-Dunckley E, Jacobson S, Belden C, Davis K (2014) Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett 571:34–38. https://doi.org/10.1016/j.neulet.2014.04.027 CrossRefPubMedPubMedCentral

Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987–2007. Cell Tissue Bank 9:229–245. https://doi.org/10.1007/s10561-008-9067-2 CrossRefPubMedPubMedCentral

Berson DM, Castrucci AM, Provencio I (2010) Morphology and mosaics of melanopsin-expressing retinal ganglion cell types in mice. J Comp Neurol 518:2405–2422. https://doi.org/10.1002/cne.22381 CrossRefPubMedPubMedCentral

Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, Destée A (2003) Study of circadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol 26:65–72CrossRefPubMed

10.

Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA (2014) Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 71:589. https://doi.org/10.1001/jamaneurol.2014.65 CrossRefPubMedPubMedCentral

11.

Caballol N, Martí MJ, Tolosa E (2007) Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22:358–366. https://doi.org/10.1002/mds.21677 CrossRef

12.

Cai Y, Liu S, Sothern RB, Xu S, Chan P (2010) Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease. Eur J Neurol 17:550–554. https://doi.org/10.1111/j.1468-1331.2009.02848.x CrossRefPubMed

13.

Campello L, Esteve-Rudd J, Cuenca N, Martín-Nieto J (2013) The ubiquitin–proteasome system in retinal health and disease. Mol Neurobiol 47:790–810. https://doi.org/10.1007/s12035-012-8391-5 CrossRefPubMed

14.

Cuenca N, Fernández-Sánchez L, Campello L, Maneu V, De la Villa P, Lax P, Pinilla I (2014) Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res 43:17–75. https://doi.org/10.1016/j.preteyeres.2014.07.001 CrossRefPubMed

15.

Cuenca N, Herrero MT, Angulo A, De Juan E, Martínez-Navarrete GC, López S, Barcia C, Martín-Nieto J (2005) Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson’s disease. J Comp Neurol 493:261–273. https://doi.org/10.1002/cne.20761 CrossRefPubMed

16.

De Pablo-Fernández E, Courtney R, Warner TT, Holton JL (2018) A histologic study of the circadian system in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol 75:1008. https://doi.org/10.1001/jamaneurol.2018.0640 CrossRefPubMed

17.

Esquiva G, Lax P, Cuenca N (2013) Impairment of intrinsically photosensitive retinal ganglion cells associated with late stages of retinal degeneration. Invest Ophthalmol Vis Sci 54:4605–4618. https://doi.org/10.1167/iovs.13-12120 CrossRefPubMed

18.

Esquiva G, Lax P, Pérez-santonja JJ, García-fernández JM, Cuenca N (2017) Loss of melanopsin-expressing ganglion cell subtypes and dendritic degeneration in the aging human retina. Front Aging Neurosci 9:79. https://doi.org/10.3389/fnagi.2017.00079 CrossRefPubMedPubMedCentral

19.

Fahn S (2006) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14. https://doi.org/10.1111/j.1749-6632.2003.tb07458.x CrossRef

20.

Fernandez DC, Chang Y-T, Hattar S, Chen S-K (2016) Architecture of retinal projections to the central circadian pacemaker. Proc Natl Acad Sci 113:6047–6052. https://doi.org/10.1073/pnas.1523629113 CrossRefPubMed

21.

Ferreira M, Massano J (2017) An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol Scand 135:273–284. https://doi.org/10.1111/ane.12616 CrossRefPubMed

22.

Fifel K (2017) Alterations of the circadian system in Parkinson’s disease patients. Mov Disord 32:682–692. https://doi.org/10.1002/mds.26865 CrossRefPubMed

23.

Fifel K, Vezoli J, Dzahini K, Claustrat B, Leviel V, Kennedy H, Procyk E, Dkhissi-Benyahya O, Gronfier C, Cooper HM (2014) Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates. PLoS One 9:e86240. https://doi.org/10.1371/journal.pone.0086240 CrossRefPubMedPubMedCentral

24.

Fifel K, Videnovic A (2018) Light therapy in Parkinson’s disease: towards mechanism-based protocols. Trends Neurosci 41:252–254. https://doi.org/10.1016/j.tins.2018.03.002 CrossRefPubMed

25.

Hannibal J, Christiansen AT, Heegaard S, Fahrenkrug J, Kiilgaard JF (2017) Melanopsin expressing human retinal ganglion cells: subtypes, distribution, and intraretinal connectivity. J Comp Neurol 525:1934–1961. https://doi.org/10.1002/cne.24181 CrossRefPubMed

26.

Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31:2473–2475PubMed

27.

Hattar S (2002) Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 295:1065–1070. https://doi.org/10.1126/science.1069609 CrossRefPubMedPubMedCentral

28.

Hattar S, Kumar M, Park A, Tong P, Tung J, Yau K-W, Berson DM (2006) Central projections of melanopsin-expressing retinal ganglion cells in the mouse. J Comp Neurol 497:326–349. https://doi.org/10.1002/cne.20970 CrossRefPubMedPubMedCentral

29.

Högl B (2017) Circadian rhythms and chronotherapeutics - underappreciated approach to improving sleep and wakefulness in Parkinson disease. JAMA Neurol 74:387–388. https://doi.org/10.1001/jamaneurol.2016.5519 CrossRefPubMed

30.

Ksendzovsky A, Pomeraniec IJ, Zaghloul KA, Provencio JJ, Provencio I (2017) Clinical implications of the melanopsin-based non–image-forming visual system. Neurology 88:1282–1290. https://doi.org/10.1212/WNL.0000000000003761 CrossRefPubMedPubMedCentral

31.

La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, Sambati L, Pan BX, Tozer KR, Barboni P, Provini F, Avanzini P, Carbonelli M, Pelosi A, Chui H, Liguori R, Baruzzi A, Koronyo-Hamaoui M, Sadun AA, Carelli V (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol 79:90–109. https://doi.org/10.1002/ana.24548 CrossRefPubMed

32.

La Morgia C, Ross-Cisneros FN, Sadun AA, Carelli V (2017) Retinal ganglion cells and circadian rhythms in Alzheimer’s disease, Parkinson’s disease, and beyond. Front Neurol 8:1–8. https://doi.org/10.3389/fneur.2017.00162 CrossRef

33.

Langhammer CG, Previtera ML, Sweet ES, Sran SS, Chen M, Firestein BL (2010) Automated Sholl analysis of digitized neuronal morphology at multiple scales: whole-cell Sholl analysis vs. Sholl analysis of arbor sub-regions. Cytometry A 77:1160–1168. https://doi.org/10.1002/cyto.a.20954 CrossRefPubMedPubMedCentral

34.

Lax P, Esquiva G, Fuentes-Broto L, Segura F, Sánchez-Cano A, Cuenca N, Pinilla I (2016) Age-related changes in photosensitive melanopsin-expressing retinal ganglion cells correlate with circadian rhythm impairments in sighted and blind rats. Chronobiol Int 33:374–391. https://doi.org/10.3109/07420528.2016.1151025 CrossRefPubMed

35.

Lazzerini Ospri L, Prusky G, Hattar S (2017) Mood, the circadian system, and melanopsin retinal ganglion cells. Annu Rev Neurosci 40:539–556. https://doi.org/10.1146/annurev-neuro-072116-031324 CrossRefPubMed

36.

Li S, Wang Y, Wang F, Hu L-F, Liu C-F (2017) A new perspective for Parkinson’s disease: circadian rhythm. Neurosci Bull 33:62–72. https://doi.org/10.1007/s12264-016-0089-7 CrossRefPubMed

37.

Li Z, Tian T (2017) Light therapy promoting dopamine release by stimulating retina in Parkinson disease. JAMA Neurol 74:1267. https://doi.org/10.1001/jamaneurol.2017.1906 CrossRefPubMed

38.

Liao HW, Ren X, Peterson BB, Marshak DW, Yau KW, Gamlin PD, Dacey DM (2016) Melanopsin-expressing ganglion cells on macaque and human retinas form two morphologically distinct populations. J Comp Neurol 524:2845–2872. https://doi.org/10.1002/cne.23995 CrossRefPubMedPubMedCentral

39.

Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, Devick S, Cronin R, Adler CH (2015) Abnormal visual contrast acuity in Parkinson’s disease. J Parkinsons Dis 5:125–130. https://doi.org/10.3233/JPD-140470 PubMedCrossRef

40.

Lucas RJ, Douglas RH, Foster RG (2001) Characterization of an ocular photopigment capable of driving pupillary constriction in mice. Nat Neurosci 4:621–626. https://doi.org/10.1038/88443 CrossRefPubMed

41.

Malhotra RK (2018) Neurodegenerative Disorders and Sleep. Sleep Med Clin 13:63–70. https://doi.org/10.1016/j.jsmc.2017.09.006 CrossRefPubMed

42.

Martino JK, Freelance CB, Willis GL (2018) The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study. Sleep Med 44:24–31. https://doi.org/10.1016/j.sleep.2018.01.001 CrossRefPubMed

43.

Micieli G, Tosi P, Marcheselli S, Cavallini A (2003) Autonomic dysfunction in Parkinson’s disease. Neurol Sci 24:32–34. https://doi.org/10.1007/s100720300035 CrossRef

44.

Obara EA, Hannibal J, Heegaard S, Fahrenkrug J (2017) Loss of melanopsin-expressing retinal ganglion cells in patients with diabetic retinopathy. Investig Opthalmology Vis Sci 58:2187. https://doi.org/10.1167/iovs.16-21168 CrossRef

45.

Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N (2018) Phosphorylated α-synuclein in the retina is a biomarker of Parkinson’s disease pathology severity. Mov Disord. https://doi.org/10.1002/mds.27392

46.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424 CrossRefPubMed

47.

Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD (2000) A novel human opsin in the inner retina. J Neurosci 20:600–605CrossRefPubMed

48.

Provencio I, Rollag MD, Castrucci AM (2002) Photoreceptive net in the mammalian retina. This mesh of cells may explain how some blind mice can still tell day from night. Nature 415:493. https://doi.org/10.1038/415493a CrossRefPubMed

49.

Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87:387–406PubMedPubMedCentral

50.

Tan LCS (2012) Mood disorders in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S74–S76. https://doi.org/10.1016/S1353-8020(11)70024-4 CrossRefPubMed

51.

Vezoli J, Fifel K, Leviel V, Dehay C, Kennedy H, Cooper HM, Gronfier C, Procyk E (2011) Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson’s disease. PLoS One 6:e23952. https://doi.org/10.1371/journal.pone.0023952 CrossRefPubMedPubMedCentral

52.

Videnovic A, Golombek D (2013) Circadian and sleep disorders in Parkinson’s disease. Exp Neurol 243:45–56. https://doi.org/10.1016/j.expneurol.2012.08.018 CrossRefPubMed

53.

Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC (2017) Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease a randomized clinical trial. JAMA Neurol 74:411–418. https://doi.org/10.1001/jamaneurol.2016.5192 CrossRefPubMedPubMedCentral

54.

Wang C-A, McInnis H, Brien DC, Pari G, Munoz DP (2016) Disruption of pupil size modulation correlates with voluntary motor preparation deficits in Parkinson’s disease. Neuropsychologia 80:176–184. https://doi.org/10.1016/J.NEUROPSYCHOLOGIA.2015.11.019 CrossRefPubMed

55.

Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR (2016) Visual dysfunction in Parkinson’s disease. Brain 139:2827–2843. https://doi.org/10.1093/brain/aww175 CrossRefPubMedPubMedCentral

56.

Willison LD, Kudo T, Loh DH, Kuljis D, Colwell CS (2013) Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson’s disease: insights from a transgenic mouse model. Exp Neurol 243:57–66. https://doi.org/10.1016/j.expneurol.2013.01.014 CrossRefPubMedPubMedCentral

57.

Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G (2011) Sleep disorders and the natural history of Parkinson’s disease: the contribution of epidemiological studies. Sleep Med Rev 15:41–50. https://doi.org/10.1016/j.smrv.2010.02.004 CrossRefPubMed

Title: Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease
Authors: Isabel Ortuño-Lizarán
Gema Esquiva
Thomas G. Beach
Geidy E. Serrano
Charles H. Adler
Pedro Lax
Nicolás Cuenca
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2018
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/s40478-018-0596-z

At a glance: The STEP trials

Springer Medicine

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Skeletal myopathy in Pompe disease: a failure of satellite cell activation?

Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin

CNS-border associated macrophages respond to acute ischemic stroke attracting granulocytes and promoting vascular leakage

ABCA1 haplodeficiency affects the brain transcriptome following traumatic brain injury in mice expressing human APOE isoforms

D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model

Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease